Session 117 - 12th CROI

Home

Session 117 Poster Abstracts
HIV Drug Resistance: Selection, Evolution, and Persistence
Wednesday, 1:30 - 3:30 pm
Hall A

676	Differential Evolution of Cell-free and Cell-associated HIV-1 in Blood and Vaginal Tract Grissell Tirado*¹, G Jove¹, E Reyes², G Sepulveda³, Y Yamamura¹, and A Kumar¹ ¹Ponce Sch of Med, Puerto Rico; ²Dept of Hlth Immunology Clin, Arecibo, Puerto Rico; and ³Dept of Hlth Immunology Clin, Ponce, Puerto Rico
677	Recombination Is Frequent in HIV-1 Populations in both Drug Naïve and Drug-resistant Patients Frank Maldarelli*¹, M Kearney¹, S Palmer¹, M Polis², J Mican², R Stephens³, D Rock², J Mellors⁴, and J Coffin¹ ¹NCI-Frederick, NIH, DHHS, MD, USA; ²NIAID, Bethesda, MD, USA; ³SAIC-Frederick, MD, USA; and ⁴Univ of Pittsburgh, PA, USA
678	Limited Evolution of Drug Resistance in HIV-1-infected Patients with Persistent Low-level Viremia on a Stable Antiretroviral Regimen for Longerr than 1 Year Caryn Morse*¹, F Maldarelli², R Dewar³, C Rehm⁴, and J Kovacs¹ ¹NIAID-CC HIV/AIDS Program, Critical Care Medicine Department, NIH Clinical Center, Bethesda, MD; ²NCI-Frederick, NIH, DHHS, MD, USA; ³SAIC-Frederick, MD, USA; and ⁴NIAID, Bethesda, MD, USA
679	Selection of Drug-resistance Mutations in Chronic HIV-infected Patients during Therapy Interruptions Guided by CD4+ T-cell Counts and Viral Load Levels: The Tibet Study Lidia Ruiz*¹, J Romeu², J Martínez-Picado¹, R Bellido¹, J Llibre³, P Domingo⁴, G Tambussi⁵, B Clotet⁶, and on behalf of the Tibet Study Group. ¹Fndn Irsicaixa, Hosp Univ Germans Trias i Pujol, Badalona, Barcelona, Spain; ²Hosp Univ Germans Trias i Pujol, Badalona, Spain; ³Hosp Sant Jaume, Calella, Barcelona, Spain; ⁴Hosp de la Santa Creu i Sant Pau, Autonomous Univ of Barcelona, Spain; ⁵Hosp San Raffaele, Milan, Italy; and ⁶Fndn Irsicaixa, Hosp Univ Germans Trias i Pujol, Badalona, Barcelona, Spain
680	Interruption of Enfuvirtide in Patients with Enfuvirtide Resistance Steven Deeks*¹, J Lu², R Hoh¹, G Beatty¹, W Huang³, C Petropoulos³, and D Kuritzkes² ¹Univ of California, San Francisco, USA; ²Partners AIDS Res Ctr, Boston, MA, USA; and ³ViroLogic, Inc, South San Francisco, CA, USA
681	Dynamics of Protease Inhibitor-resistance Mutations during Treatment Interruptions Francesca Ceccherini-Silberstein*¹, C Gori², M Santoro¹, V Svicher¹, F Forbici², R D'Arrigo², M Bellocchi², N Esposito¹, M Zaccarelli², A Bertoli¹, A Cenci¹, M Trotta², V Tozzi², A Antinori², and C F Perno^1,2 ¹Univ of Rome 'Tor Vergata', Italy and ²INMI L Spallanzani, Rome, Italy
682	A New Pigtail Macaque RT-SHIV Model of NNRTI Therapy and Resistance Zandrea Ambrose*¹, J Lifson¹, J Kimata², V Boltz¹, F Maldarelli¹, S Palmer¹, J Mellors³, J Coffin¹, S Hughes¹, and V KewalRamani¹ ¹NCI-Frederick, NIH, DHHS, MD, USA; ²Baylor Coll of Med, Houston, TX, USA; and ³Univ of Pittsburgh Sch of Med, PA, USA
683	Role of HIV-1 Mminority Populations on Resistance Mutational Patterns Evolution after Nelfinavir Failure and Susceptibility to Protease Inhibitors Anne-Genevieve Marcelin*¹, B Roquebert¹, I Malet¹, M Wirden¹, C Katlama², and V Calvez¹ ¹Hosp Pitie-Salpetriere, Paris, France and ²Hosp Pitie-Salpetriere, Paris, France
684	Evolution in the Diversity of HIV-1-resistance Mutation Patterns in >128,000 Clinical Samples Received for Resistance Analysis from 1998 to 2004 Alex Rinehart*¹, P Lecocq², T Pattery², B Wasikowsi³, and L Bacheler¹ ¹Virco Lab, Inc, Durham, NC, USA; ²Virco BVBA, Mechelen, Belgium; and ³xLeo, Inc, Raleigh, NC, USA